Helsinn to co promote Zykadia (ceritinib)in USA for patients with ALK-positive metastatic non-small cell lung cancer.- Novartis.
Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, announced that its US subsidiary Helsinn Therapeutics (US), Inc. (HTU) has signed a co-promotion agreement with Novartis for Zykadia (ceritinib), an approved treatment for patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) as detected with an FDA approved test.
As part of the agreement, Novartis has granted a non-exclusive, non-sublicensable right to HTU to provide detailing services for Zykadia in the US. Novartis will retain all other activities in the US, including marketing and development. HTU cancer sales team will begin their services for Zykadia on 5 September 2017.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins